Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2024 - 2025)

Xilio Therapeutics' Depreciation & Amortization (CF) history spans 2 years, with the latest figure at $340000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 10.53% year-over-year to $340000.0; the TTM value through Sep 2025 reached $1.6 million, changed N/A, while the annual FY2024 figure was $1.6 million, 13.47% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $340000.0 at Xilio Therapeutics, down from $381000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $497000.0 in Q1 2025 and bottomed at $340000.0 in Q3 2025.